Shouval et al. recently added to this list of prognostic factors two frequent AML‐related mutations: FLT3–ITD and NPM1 demonstrating that molecular subtype is a strong predictor of LFS, OS, and relapse and that AML patients with intermediate‐risk cytogenetics expressing the FLT3‐ITDneg/NPM1mut mutation phenotype experience favorable outcomes when autografted in CR1 with a 5‐year LFS of 62% and OS of 74% indicating that ACT is an attractive option for these patients.7 Here, FLT3 is linked to acute myeloid leukemia.